REtroperitoneal SArcoma Registry: an International Prospective Initiative
RESAR
1 other identifier
observational
2,000
11 countries
22
Brief Summary
Surgery is currently the only potentially curative treatment modality for localized retroperitoneal sarcoma (RPS). Available studies regarding oncologic outcomes are mainly retrospective in nature, and RPS are recognized as a rare disease. Therefore, prospective analysis of high quality data is a top priority. Primary Objectives of this study are:
- to prospectively collect standardized clinical data and radiological and pathological material from primary RPS patients treated with surgery at reference centers.
- patient outcome will be evaluated in terms of overall survival (OS), disease-free survival (DFS), crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM). Secondary Objectives:
- to estimate the efficacy and safety of surgical treatment, including extended surgical approach to primary RPS;
- to prospectively evaluate the impact of multimodality therapy, including radiation therapy and chemotherapy;
- to identify clinical, radiological and pathological characteristics that may influence the oncological outcome or may be used as predictors of LR/DM/OS. These may be important biomarkers of disease;
- to utilize collected pathological material for research collaborations.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2016
Longer than P75 for all trials
22 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2016
CompletedFirst Submitted
Initial submission to the registry
March 29, 2018
CompletedFirst Posted
Study publicly available on registry
February 12, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
ExpectedFebruary 12, 2019
February 1, 2019
4.3 years
March 29, 2018
February 11, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Disease-free Survival
Survival after surgery for primary RPS resection; any disease recurrence, local or distant, will be considered as an event at time of first radiological appearance.
10 years
Secondary Outcomes (4)
Overall Survival
10 years
Crude cumulative incidence of Local recurrence
10 years
Crude cumulative incidence of Distant metastasis
10 years
Morbidity
60 days
Eligibility Criteria
Patients diagnosed with a primary RPS amenable to surgical resection.
You may qualify if:
- primary RPS operated on in the participating center;
- age\>18 years at the time of the first treatment (pediatric patients can not be included)
- histological confirmed diagnosis according to the WHO criteria done on biopsy or surgical specimen by dedicated sarcoma pathologist;
- radiological examinations performed (contrast enhanced abdominal CT scan and/or MRI) prior to surgical resection;
- signed informed consent form;
- adequate compliance of the patients to the plan of follow-up
You may not qualify if:
- age\<18 years;
- recurrent tumor;
- benign retroperitoneal tumors;
- serious psychiatric disease that precludes informed consent or limits compliance;
- impossibility to ensure adequate follow-up
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (22)
University of Southern California (USC)
Los Angeles, California, 90033, United States
Mayo Clinic
Jacksonville, Florida, 32224, United States
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Winship Cancer Institute
Emory, Georgia, 30322, United States
Brigham and Women's Hospital/Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
The Ohio State University
Columbus, Ohio, 43210, United States
Peter MacCallum Cancer Center
Melbourne, Australia
Maisonneuve-Rosemont Hospital / University of Montreal
Montreal, Canada
The Ottawa Hospital
Ottawa, Canada
Mount Sinai / Princess Margaret
Toronto, Canada
Institut Curie
Paris, France
University Medical Center and Medical Faculty Mannheim, University of Heidelberg
Mannheim, Germany
Ludwig Maximilian University
Munich, Germany
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
Veneto Institute of Oncology
Padua, Italy
Ospedale Borgo Roma
Verona, Italy
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
Warsaw, Poland
Institute of Oncology Ljubljana
Ljubljana, Slovenia
Samsung Medical Center
Seoul, South Korea
Hospital Clinico Universitario "Virgen de la Arrixaca"
Murcia, Spain
University Hospital Birmingham (Queen Elizabeth)
Birmingham, United Kingdom
Royal Marsden Hospital
London, United Kingdom
Related Publications (6)
Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honore C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE, Raut CP. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. Ann Surg. 2016 May;263(5):1002-9. doi: 10.1097/SLA.0000000000001447.
PMID: 26727100BACKGROUNDTrans-Atlantic RPS Working Group. Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol. 2015 Jan;22(1):256-63. doi: 10.1245/s10434-014-3965-2. Epub 2014 Oct 15.
PMID: 25316486BACKGROUNDMacNeill AJ, Gronchi A, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honore C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE, Barretta F, Raut CP, Strauss DC. Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group. Ann Surg. 2018 May;267(5):959-964. doi: 10.1097/SLA.0000000000002250.
PMID: 28394870BACKGROUNDBenuzzi L, Iadecola S, Fiore M, Baia M, Colombo C, Radaelli S, Di Blasi E, Morosi C, Sanfilippo R, Callegaro D, Gronchi A. Pancreaticoduodenectomy and IVC resection in retroperitoneal sarcoma: Expanding the limits of feasible surgery. Eur J Surg Oncol. 2026 Jan;52(1):110547. doi: 10.1016/j.ejso.2025.110547. Epub 2025 Oct 26.
PMID: 41176815DERIVEDXiao M, Li X, Bu F, Ma S, Yang X, Chen J, Zhao Y, Cananzi F, Luo C, Min L. Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study. Elife. 2025 May 23;14:RP100887. doi: 10.7554/eLife.100887.
PMID: 40407808DERIVEDZhao Y, Qin D, Li X, Wang T, Zhang T, Rao X, Min L, Wan Z, Luo C, Xiao M. Identification of NINJ1 as a novel prognostic predictor for retroperitoneal liposarcoma. Discov Oncol. 2024 May 11;15(1):155. doi: 10.1007/s12672-024-01016-x.
PMID: 38733554DERIVED
Related Links
Biospecimen
Biopsies, Surgical specimen
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alessandro Gronchi, MD
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- STUDY DIRECTOR
Marco Fiore, MD
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 29, 2018
First Posted
February 12, 2019
Study Start
September 1, 2016
Primary Completion
December 31, 2020
Study Completion (Estimated)
December 31, 2030
Last Updated
February 12, 2019
Record last verified: 2019-02